STELARA®
has been clinically studied for 19 years 1 *
4 DOSES PER YEAR
Convenient dosing schedule every 12 weeks after 2 starter doses at Weeks 0 and 4.
LEARN MOREJANSSEN CAREPATH
FOR STELARA® (ustekinumab)
FOR STELARA® (ustekinumab)
Janssen CarePath helps your patients start and stay on STELARA® that you've prescribed.
LEARN MOREJANSSEN LINK
FOR STELARA® (ustekinumab)
FOR STELARA® (ustekinumab)
When commercial insurance is delayed (>5 business days) or denied, your eligible patients who have been prescribed subcutaneous STELARA® will receive subcutaneous STELARA® at no cost until they receive insurance coverage. Not valid for individuals who use any state or federal government-funded healthcare program to cover a portion of medication costs, such as Medicare, Medicaid, TRICARE, Department of Defense, or Veterans Administration. For medication only. Terms expire at the end of each program year and may change.
LEARN MORESTELARA®:
A LEGACY IN THE TREATMENT OF PLAQUE PSORIASIS
More than 8000 dermatologists have prescribed STELARA® in the
United States1 † ‡
More than 300,000 adult patients with moderate to severe plaque psoriasis treated with STELARA® in the
United States1 §
STELARA® has an estimated cumulative exposure of
1,600,000 patient-years
worldwide since launch1 ║
*A phase 1 clinical trial of STELARA® was initiated in 2001 in patients with moderate to severe plaque psoriasis. Phase 3, double-blind, placebo-controlled, multicenter trials PHOENIX 1 and PHOENIX 2 began in 2005 and 2006, respectively.
†IQVIA-Xponent data. Dermatologists who have written at least 1 prescription for STELARA® in the United States from July 2017 to August 2019.
‡Reflects usage across all lines of therapy.
§More than 300,000 adult patients treated with STELARA ® in the United States from September 2009 to December 2019. Estimations are based on calculations using product-utilization data collected in the United States for STELARA ® to determine patient type, average dose per administration, total number of administrations, and patient persistency rates.
║Based on worldwide estimated number of patient-years from launch through December 2019. Patient-years were estimated by calculations using STELARA ® distribution data to determine average yearly dose while considering regional estimates of patient compliance to dosing regimen.
Reference: 1. Data on file. Janssen Biotech, Inc.
cp-168045v3 05/23
No footer links content fetched